HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sallan, S. E. Search for Related Content PubMed PubMed Citation Articles by Sallan, S. E. Social Bookmarking                   What's this?

Myths and Lessons from the Adult/Pediatric Interface in Acute Lymphoblastic Leukemia

Correspondence: Stephen Sallan, MD, Dana Farber Cancer Institute, 44 Binney St, Rm 1642, Boston MA 02115-6084; Phone 617-632-3316; Fax 617-632-5511; Email stephen_sallan{at}dfci.harvard.edu

Abstract

The development of effective therapy for children with acute lymphoblastic leukemia (ALL) is one of the great successes of clinical oncology, with long-term survival achieved in over 80% of patients. However, cure rates for adults with ALL remain relatively low, with only 40% of patients cured. With an age-unrestricted, biology-based approach, we anticipate a better understanding about why these outcome differences exist, and think that by extending successful pediatric clinical programs to include adult patients with ALL, we can directly compare uniformly treated adults and children in terms of response to therapy, toxicity and underlying biology.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?